DexCom (NasdaqGS:DXCM) is seeing higher adoption of its continuous glucose monitoring systems among patients using GLP-1 drugs, as physicians pair both therapies for diabetes care. The company is ...
Q4 2025 Earnings Call February 12, 2026 4:30 PM ESTCompany ParticipantsSean Christensen - Vice President of Finance and ...
Earnings call Dexcom delivered Q4 2025 revenue of $1.26B (+13% YoY), exceeding guidance, with gross margin expanding 410 bps YoY to 63.5%. FY25 free cash flow surpassed $1B. For FY26, guidance calls ...
Credence Research Inc. has released a new study on the Blood Glucose Monitoring Devices Market. According the report the ...
A major wrongful death lawsuit has been filed alleging defects in Abbott Laboratories' (NYSE:ABT) FreeStyle Libre 3 and Libre 3 Plus glucose monitoring systems. The claim links the products to seven ...
Expert Consumers has recognized Westgate Resorts for its top-rated Las Vegas vacation packages in 2026, citing the company's value-driven pricing, entertainment access, and range of on-site amenities.
Fifteen medtech companies, including Boston Scientific and Medtronic, rank on Forbes’ 2026 list of America’s best ...
Autonomous Vehicles, ML, Quantum computing, smart homes, Telemedicine, Wearable devices The Intersection of Technology and ...
MedPage Today on MSN
GLP-1s bringing back scurvy? Achondroplasia drug win; intermittent fasting flop
News and commentary from the endocrinology world ...
People have been riding the GLP-1 wave to achieve quick and significant weight loss. But given the drug’s effect on controlling type 2 diabetes, it’s no surprise that DexCom CEO Jake Leach wants to ...
The accompanying press release dated February 12, 2026 contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross profit margin, non-GAAP operating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results